Abstract
Large trials have shown that hydroxyethyl starch increases the risk of death, kidney injury, and bleeding. However, an EMA review last year permitted continued use in some patients, overturning an earlier decision to withdraw the product completely. Christiane Hartog and colleagues discuss the evidence and call on doctors to avoid using starch formulations
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Blood Coagulation Disorders / chemically induced
-
Critical Illness / therapy
-
Evidence-Based Medicine / standards
-
Hemorrhagic Disorders / chemically induced
-
Humans
-
Hydroxyethyl Starch Derivatives / adverse effects*
-
Hydroxyethyl Starch Derivatives / therapeutic use
-
Hypovolemia / drug therapy
-
Intracranial Hemorrhages / chemically induced
-
Legislation, Drug
-
Plasma Substitutes / adverse effects*
-
Plasma Substitutes / therapeutic use
-
Renal Insufficiency / chemically induced
-
Risk Factors
-
Sepsis / therapy
-
United Kingdom
-
United States
-
United States Food and Drug Administration
Substances
-
Hydroxyethyl Starch Derivatives
-
Plasma Substitutes